FULC: Fulcrum Therapeutics, Inc. Common Stock Company Profile & Statistics

About

Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on genetically defined diseases with an initial focus on rare diseases. Fulcrum Therapeutics Inc. is based in Cambridge, United States.

Info & Links

CEO

Alex C. Sapir

Headquarters

26 LANDSDOWNE STREET
CAMBRIDGE, MA 02139, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

Fulcrum Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

350.60M

Enterprise Value

292.38M

Enterprise Value/EBITDA(ttm)

-14.40

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

74.03

Price to Book(mrq)

0.93

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

Profit Margin(ttm)

17.32%

Return on Equity(ttm)

-7.31%

Return on Invested Capital(ttm)

-7.59%

Return on Assets(ttm)

-6.74%

Income Statement

Revenue(ttm)

80.00M

Revenue Per Share(ttm)

1.48

Gross Profit(ttm)

80.00M

EBITDA(ttm)³

-20.30M

Net Income Available to Common(ttm)

-9.73M

Diluted EPS(ttm)

-0.31

Share Statistics

Beta (5Y Monthly)

2.03

52-Week Change

-11.61%

S&P 500 52-Week Change

12.35%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

53.98M

Dividend Yield

0.00%

Float⁴

51.73M

% Held by Insiders

4.10%

% Held by Institutions

89.83%

Balance Sheet

Total Cash(mrq)

241.02M

Total Cash Per Share(mrq)

4.47

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

22.63%

Quick Ratio(mrq)

18.44%

Book Value Per Share(mrq)

4.50

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.04

Free Cash Flow(ytd)

-2.50M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

FULC

Fulcrum Therapeutics, Inc. Common Stock

Fulcrum Therapeutics, Inc. Common Stock Profile